S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
Learn how to make more money in 24 hours than most folks make all year long...This could be the easiest way to turn $5,000 into $196,868.

NASDAQ:HITK - Hi-Tech Pharmacal Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Hi-Tech Pharmacal Co, Inc is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and over-the-counter (OTC) brands. It produces a range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care and other conditions. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:HITK
CUSIP42840B10
Phone+1-516-7898228

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive HITK News and Ratings via Email

Sign-up to receive the latest news and ratings for HITK and its competitors with MarketBeat's FREE daily newsletter.


Hi-Tech Pharmacal (NASDAQ:HITK) Frequently Asked Questions

What is Hi-Tech Pharmacal's stock symbol?

Hi-Tech Pharmacal trades on the NASDAQ under the ticker symbol "HITK."

Has Hi-Tech Pharmacal been receiving favorable news coverage?

Media headlines about HITK stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hi-Tech Pharmacal earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media headlines about the healthcare company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Hi-Tech Pharmacal.

Who are some of Hi-Tech Pharmacal's key competitors?

What other stocks do shareholders of Hi-Tech Pharmacal own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hi-Tech Pharmacal investors own include Ensco Rowan (ESV), KINGFISHER PLC/SH (KGFHY), Alexion Pharmaceuticals (ALXN), Allos Therapeutics (ALTH), Acacia Research (ACTG), Altaba (AABA), Tesco (TSCO), Tethys Petroleum (TPL), Secure Trust Bank (STB) and Severfield (SFR).

What is Hi-Tech Pharmacal's official website?

The official website for Hi-Tech Pharmacal is http://www.hitechpharm.com/.

How can I contact Hi-Tech Pharmacal?

Hi-Tech Pharmacal's mailing address is 369 Bayview Ave, AMITYVILLE, NY 11701-2801, United States. The healthcare company can be reached via phone at +1-516-7898228.


MarketBeat Community Rating for Hi-Tech Pharmacal (NASDAQ HITK)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  92 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  171
MarketBeat's community ratings are surveys of what our community members think about Hi-Tech Pharmacal and other stocks. Vote "Outperform" if you believe HITK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HITK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel